At AACE 2017, John Bilezikian, MD, Professor of Medicine and Pharmacology at the College of Physicians & Surgeons, Columbia University, Chief, Emeritus, of the of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center discussed the latest FDA approval of Tymlos for postmenopausal women with osteoporosis and for women who are at high risk for fracture.
“The development of this drug was very beautifully designed, and it turns out as the clinical trials were developed, that this drug proved itself, that it did do what we thought it would do.” Tymlos was found to markedly increase bone density in a very significant way and reduce fractures in postmenopausal women both at and outside the vertebral column.
source
